



Published in final edited form as:

J Allergy Clin Immunol. 2015 January ; 135(1): 290–291. doi:10.1016/j.jaci.2014.09.037.

β_2 -Agonist therapy may contribute to the air pollution and IL-6–associated risk of developing severe asthma with dual-positive T_H2/T_H17 cells

Sergio E. Chiarella, MD^a, G. R. Scott Budinger, MD^b, and Gökhan M. Mutlu, MD^c

Gökhan M. Mutlu: gmutlu@uchicago.edu

^aDivision of Allergy and Immunology, Northwestern University, Chicago, Ill

^bDivision of Pulmonary and Critical Care Medicine, Northwestern University, Chicago, Ill

^cSection of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Ill

To the Editor

We read the recently published manuscript by Irvin et al¹ with great interest. The authors identified 3 distinct subgroups of asthma based on CD4 T-cell analysis in bronchoalveolar lavage fluid: T_H2 predominant, T_H2/T_H17 predominant, and T_H2/T_H17^{low} . The T_H2/T_H17 predominant subgroup was defined as patients with T_H2 -predominant asthma whose T_H2 cells coexpress IL-17. Patients in this subgroup with increased numbers of dual-positive T_H2/T_H17 cells had significantly more airflow limitation and increased airway reactivity in response to methacholine challenge and higher numbers of eosinophils in their blood when compared with patients in the other subgroups. Furthermore, T_H2/T_H17 cells were also resistant to steroid-induced cell death.

In their discussion they proposed T_H2 cells as the most likely precursors for T_H2/T_H17 cells.² They speculated that environmental factors known to aggravate asthma, such as air pollution, might be responsible for the differentiation of T_H2 cells into T_H2/T_H17 cells through their ability to induce IL-6, which induces differentiation of T_H2/T_H17 cells from T_H2 cells.^{1–4} They suggested that patients with T_H2 -predominant asthma can switch their endotype to T_H2/T_H17 -predominant asthma over time in the presence of increased IL-6 production because of recurrent respiratory tract infections or exposure to environmental toxicants, such as air pollution.^{1,3–5}

We agree with the authors' conclusion. In human subjects exposure to particulate matter (PM) air pollution is associated with impaired lung development, worsening lung function, and increased asthma exacerbations.^{6–9} Supporting the role of air pollution as a risk factor for the development of T_H2/T_H17 -predominant asthma, we previously reported that mice exposed to PM air pollution have a dose-dependent lung inflammation characterized by the release of IL-6, which was the predominant proinflammatory cytokine in the lungs.^{10,11} We

Disclosure of potential conflict of interest: G. R. S. Budinger has received research support from the National Institutes of Health (NIH) and is Deputy Editor of the American Thoracic Society (ATS). G. M. Mutlu has received research support from the NIH and is Associate Editor of the ATS. S. Chiarella declares that he has no relevant conflicts of interest.

have recently published that the administration of β_2 -adrenergic agonists, such as formoterol, causes a further increase in IL-6 release after exposure to PM. Furthermore, administration of short-acting β_2 -adrenergic agonists, such as albuterol, augmented the PM-induced IL-6 release from primary human alveolar macrophages.¹² In view of these results by Irvin et al¹ and our recent findings about the effect of β_2 -adrenergic receptor stimulation on IL-6 release during exposure to air pollution, we speculate that increased β_2 -agonist therapy use in patients who reside in areas of higher levels of PM air pollution might contribute to the induction of T_H2/T_H17 cells.

Acknowledgments

Supported by National Institutes of Health grants R01 ES015024 (to G.M.M.) and R01 ES013995 (to G.R.S.B.).

References

1. Irvin C, Zafar I, Good J, Rollins D, Christianson C, Gorska MM, et al. Increased frequency of dual-positive T2/T17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma. *J Allergy Clin Immunol*. Jul 18.2014 [Epub ahead of print]. 10.1016/j.jaci.2014.05.038
2. Wang YH, Voo KS, Liu B, Chen CY, Uygungil B, Spoede W, et al. A novel subset of CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. *J Exp Med*. 2010; 207:2479–91. [PubMed: 20921287]
3. Tabarani CM, Bonville CA, Suryadevara M, Branigan P, Wang D, Huang D, et al. Novel inflammatory markers, clinical risk factors and virus type associated with severe respiratory syncytial virus infection. *Pediatr Infect Dis J*. 2013; 32:e437–42. [PubMed: 23804121]
4. Thompson AM, Zanobetti A, Silverman F, Schwartz J, Coull B, Urch B, et al. Baseline repeated measures from controlled human exposure studies: associations between ambient air pollution exposure and the systemic inflammatory biomarkers IL-6 and fibrinogen. *Environ Health Perspect*. 2010; 118:120–4. [PubMed: 20056584]
5. Ruckerl R, Ibaldo-Mulli A, Koenig W, Schneider A, Woelke G, Cyrys J, et al. Air pollution and markers of inflammation and coagulation in patients with coronary heart disease. *Am J Respir Crit Care Med*. 2006; 173:432–41. [PubMed: 16293802]
6. Downs SH, Schindler C, Liu LJ, Keidel D, Bayer-Oglesby L, Brutsche MH, et al. Reduced exposure to PM10 and attenuated age-related decline in lung function. *N Engl J Med*. 2007; 357:2338–47. [PubMed: 18057336]
7. Dockery DW, Pope CA III, Xu X, Spengler JD, Ware JH, Fay ME, et al. An association between air pollution and mortality in six U.S. cities. *N Engl J Med*. 1993; 329:1753–9. [PubMed: 8179653]
8. Gong H Jr, Linn WS, Clark KW, Anderson KR, Sioutas C, Alexis NE, et al. Exposures of healthy and asthmatic volunteers to concentrated ambient ultrafine particles in Los Angeles. *Inhal Toxicol*. 2008; 20:533–45. [PubMed: 18444007]
9. McCreanor J, Cullinan P, Nieuwenhuijsen MJ, Stewart-Evans J, Malliarou E, Jarup L, et al. Respiratory effects of exposure to diesel traffic in persons with asthma. *N Engl J Med*. 2007; 357:2348–58. [PubMed: 18057337]
10. Mutlu GM, Green D, Bellmeyer A, Baker CM, Burgess Z, Rajamannan N, et al. Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway. *J Clin Invest*. 2007; 117:2952–61. [PubMed: 17885684]
11. Budinger GR, McKell JL, Urich D, Foiles N, Weiss I, Chiarella SE, et al. Particulate matter-induced lung inflammation increases systemic levels of PAI-1 and activates coagulation through distinct mechanisms. *PLoS One*. 2011; 6:e18525. [PubMed: 21494547]
12. Chiarella SE, Soberanes S, Urich D, Morales-Nebreda L, Nigdelioglu R, Green D, et al. β_2 -Adrenergic agonists augment air pollution-induced IL-6 release and thrombosis. *J Clin Invest*. 2014; 124:2935–46. [PubMed: 24865431]